November 10, 2009 – Ascendis Pharma A/S, a privately held specialty pharmaceutical company, today announced that it has initiated a Phase I dosing study of ACP-001, a once-weekly human growth hormone prodrug. Preclinical studies in rats and monkeys have indicated that ACP-001 may have unique advantages over current treatments for human growth hormone deficiency. Benefits include fewer injections through a convenient once-weekly administration.
